889676-36-2 Usage
General Description
N,N-Diethyl 4-bromo-3-methoxybenzamide 98 is a chemical compound used in various industrial and research applications. It is a derivative of benzamide that contains a 4-bromo-3-methoxy group and a diethyl amine moiety. N,N-DIETHYL 4-BROMO-3-METHOXYBENZAMIDE 98 is commonly used as a building block for the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is known for its high purity level of 98% and is a popular choice for laboratories and research facilities. It should be handled and stored in accordance with proper safety protocols and regulations.
Check Digit Verification of cas no
The CAS Registry Mumber 889676-36-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,9,6,7 and 6 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 889676-36:
(8*8)+(7*8)+(6*9)+(5*6)+(4*7)+(3*6)+(2*3)+(1*6)=262
262 % 10 = 2
So 889676-36-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H16BrNO2/c1-4-14(5-2)12(15)9-6-7-10(13)11(8-9)16-3/h6-8H,4-5H2,1-3H3
889676-36-2Relevant articles and documents
Synthesis of18F-Difluoromethylarenes from Aryl (Pseudo) Halides
Shi, Hang,Braun, Augustin,Wang, Lu,Liang, Steven H.,Vasdev, Neil,Ritter, Tobias
supporting information, p. 10786 - 10790 (2016/09/03)
A general method for the synthesis of [18F]difluoromethylarenes from [18F]fluoride for radiopharmaceutical discovery is reported. The method is practical, operationally simple, tolerates a wide scope of functional groups, and enables the labeling of a variety of arenes and heteroarenes with radiochemical yields (RCYs, not decay-corrected) from 10 to 60 %. The18F-fluorination precursors are readily prepared from aryl chlorides, bromides, iodides, and triflates. Seven18F-difluoromethylarene drug analogues and radiopharmaceuticals including Claritin, fluoxetine (Prozac), and [18F]DAA1106 were synthesized to show the potential of the method for applications in PET radiopharmaceutical design.